Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
2-7/No data
Plasma Protein Binding %
80-84
Volume Of Distribution L/Kg
2-4
Dose For Normal Renal Function
Anesthetic induction (individualized)
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Not applicable
Supplement For Dialysis [Recommendation Level]: Pd
PD: Not applicable
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, titrate, [B]
References
Cleary JF. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol. 1997; 24: S16-13-9. [PMID: 9381223] / Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet. 1996; 31: 410-22. [PMID: 8968655] / Reilly CS, Wood AJ, Wood M. Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. Anaesthesia. 1985; 40: 837-43. [PMID: 4051149] / Wagner BK, O’ Hara DA. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet. 1997; 33: 426-53. [PMID: 9435992]